9th Annual Biomarkers Congress

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Mesothelioma Gene Therapy: The long and winding road International Mesothelioma Interest Group Meeting, Perth, Australia December, 2000
2. Gene Expression Profiling of Mesothelioma International Mesothelioma Interest Group Meeting, Perth, Australia December, 2000
3. “Cell Adhesion and the Lung” Annual Meeting of the Society of Pulmonary and Critical Care Physicians, Taipai, Taiwan December, 2000
4. “In Vivo Models to Study Angiogenesis” Annual Meeting of the Society of Pulmonary and Critical Care Physicians, Taipai, Taiwan December, 2000
5. “Gene Therapy for Mesothelioma” Annual Meeting of the Society of Pulmonary and Critical Care Physicians, Taipai, Taiwan December, 2000
6. “PECAM-1: From Bench to Bedside” University of Tennessee at Memphis, Department of Biochemistr December, 2000
7. Immuno-gene Therapy for Pleural Malignancies: Successes and Challenges University of Alabama at Birmingham Gene Therapy Center, Birmingham December, 2000
8. “Defining the Role of Cell Adhesion Molecules in Leukocyte Transmigration” New York University School of Medicine December, 2000
9. “PECAM-1: The Philadelphia Story” The Blood Center of Southeastern Wisconsin, Milwaukee, WI December, 2000
10. Gene Therapy for Localized Malignancies: Lessons Learned from a Phase 1 Clinical Trial U.C.L.A. Gene Therapy Program, Los Angeles, CA December, 2000
11. Clinical Use of Adenovirally-Delivered Herpes Simplex Thymidine Kinase to Treat Localized Malignancy Eighth International Conference on Gene Therapy of Cancer, San Diego, CA December, 2000
12. Augmenting Immunotherapy by Altering the Tumor Microenvironment. University of Nebraska, Omaha, Nebraska December, 2000
13. Connecticut Pulmonary Oxygen Toxicity in the New Millenium Yale University Pulmonary Division, New Haven December, 2000
14. Use of Ad.IFN-b to Treat Mesothelioma and Localized Malignancies - U.C.L.A. Pulmonary Division, Los Angeles, CA December, 2000
15. Use of Ad.IFN-b to Treat Localized Malignancies Tenth International Conference on Gene Therapy of Cancer, San Diego, CA December, 2000
16. “Gene Therapy for Mesothelioma” Louisiana State University Medical School, New Orleans, LA November, 2000
17. Strategies to Augment Immunotherapy , University of Auckland Cancer Centre, Auckland, New Zealand November, 2000
18. Cutting Edge Applications of Gene Therapy in the Treatment of Lung Disease 21st Annual Clinical Update of Pulmonary Disease (Deborah Heart and Lung Center, Atlantic City, NJ. November, 2000
19. Gene Therapy for Mesothelioma American College of Chest Physician, Philadelphia, PA November, 2000
20. Using Antibodies to Target Drugs , Genes, and Enzymes to the Pulmonary Circulation Maryland Thoracic Society, Baltimore Maryland November, 2000
21. “PECAM-1: An Adhesion Molecule with Signaling Properties”. McGill University Cancer Center, Montreal, Canada November, 2000
22. “PECAM-1: An Endothelial Glue” American Heart Association National Meeting November, 2000
23. Gap Junctions Play a Role in the HSVtk/GCV Bystander Effect Fourth International Conference on Cancer Gene Therapy, San Diego, CA November, 2000
24. PECAM-1: What we know and what we don't The Scripps Research Institute, La Jolla, CA November, 2000
25. Use of a TGFbeta Inhibitor to Treat Mesothelioma International Mesothelioma Interest Group Meeting, Chicago Illinois October, 2000
26. Gene Therapy for Mesothelioma Mesothelioma Applied Research Foundation National Meeting, Chicago Illinois October, 2000
27. Clinical trials using Gene Therapy for Mesothelioma , Pulmonary Division, University of Western Australia, Perth Australia October, 2000
28. Gene Therapy for Mesothelioma International Mesothelioma Group Meeting, Grantham, England October, 2000
29. External Reviewer for the National Research Centre for Asbestos Related Research, Perth Australia Perth Australia October, 2000
30. Organizing Committee International Mesothelioma Group Meeting, Grantham, England October, 2000
31. Gene Therapy and the Lung The Milton S. Hershey College of Medicine, Hershey, PA. October, 2000
32. Organizing Committee International Mesothelioma Group Meeting, Chicago, IL October, 2000
33. Gene Therapy for Mesothelioima Mesothelioma Applied Research Foundation National Meeting, Las Vegas, Nevada October, 2000
34. Animal Models of Mesothelioma International Mesothelioma Interest Group Meeting, Chicago Illinois October, 2000
35. Altering the Tumor Microenvironment to Enhance Immunotherapy International Mesothelioma Interest Group Meeting, Chicago Illinois October, 2000
36. The Role of PECAM-1 in Inflammation 1995- First International Symposium on Molecular Mechanisms of Inflammation, Schloss Ringberg, Germany. September, 2000
37. Mesothelioma: From Bench to Bedside Pennsylvania Thoracic Society, Pittsburgh, PA September, 2000
38. “Gene Therapy for Mesothelioma” University of California, San Francisco, S.F., Ca September, 2000
39. Phase I Clinical Trials using Ad.IFNbeta for Malignant Pleural Effusions Fifteenth International Conference on Gene Therapy of Cancer, Dallas, Texas September, 2000
40. Augmenting Immunotherapy Blood Center of Southeastern Wisconsin September, 2000
41. Phase I Clinical Trials using Ad.IFNbeta for Malignant Pleural Effusions Fourteenth International Conference on Gene Therapy of Cancer, Dallas, Texas September, 2000
42. Gene Therapy for Malignant Mesothelioma Third International Mesothelioma Interest Group Meeting, Paris, France September, 2000
43. Pleural Effusions, Review and Update 29th World Congress of Internal Medicine, Buenos Aires, Argentina September, 2000
44. Personalized Medicine for Lung Cancer 29th World Congress of Internal Medicine, Buenos Aires, Argentina September, 2000
45. Gene Therapy for Mesothelioma Okayama University Medical School, Okayam, Japan September, 2000
46. PECAM-1 Pulmonary Vascular Immunotargeting: A powerful force for good or evil. Harvard School of Public Health, July, 2000
47. Gene Therapy for Lung Cancer and Mesothelioma Mayo Clinic, Rochester Minnesota July, 2000
48. Role of Cell Adhesion Molecules in Asthma Asthma-95: Theory to Treatment (Joint International Meeting of the American Thoracic Society and the Academy of Allergy and Immunology), Chicago, IL. July, 2000
49. , Use of Human/SCID mouse Chimeras to Study the Role of Cell Adhesion Molecules Asthma-95: Theory to Treatment (Joint International Meeting of the American Thoracic Society and the Academy of Allergy and Immunology), Chicago, IL. July, 2000
50. Use of Ad.IFNbeta for Malignant Pleural Effusions and Mesothelioma Washington University School of Medicine, Pulmonary Division, St. Louis MO July, 2000
51. Use of Ad.IFNb in an Orthotopic Model of Lung Cancer. International Association for the Study of Lung Cancer, 11th World Conference on Lung Cancer, Barcelona, Spain July, 2000
52. Immuno-gene Therapy for Thoracic Malignancies Bank of Cyprus Oncology Centre, Nicosia, Cyprus July, 2000
53. Immuno-gene Therapy for Mesothelioma: Successes and Challenges Gene Therapy Program, Mayo Clinic Rochester, MN July, 2000
54. “Gene Therapy for Mesothelioma” University of Pittsburgh Medical Center, Pittsburgh, PA June, 2000
55. Mesothelioma Gene Therapy International Mesothelioma Interest Group Meeting, Brescia Italy June, 2000
56. Gene Therapy for Mesothelioma and Lung Cancer MD Anderson Cancer Center June, 2000
57. Role of PECAM-1 in Transmigration and Inflammation - Baylor College of Medicine, Houston, TX June, 2000
58. Planning and executing an gene therapy trial. American Society of Gene Therapy, Washington, DC June, 2000
59. Genetics, Genomics, and Gene Therapy Conference Summarizer, Aspen Lung Conference, Aspen Colorado June, 2000
60. Mechanisms Underlying Site-specific Delivery of Molecules to the Lung N.H.L.B.I. Workshop: Endothelial Cell Phenotypes in Heart, Lung, and Blood Diseases, Bethesda, MD June, 2000
61. Hot Topics in Cancer Gene Therapy American Society of Gene Therapy, Seattle, WA June, 2000
62. Use of Ad.IFNbeta for Malignant Pleural Effusions and Mesothelioma American Society of Gene Therapy, St. Louis, MO June, 2000
63. T-cell Trafficking to Tumors American Society of Gene Therapy, St. Louis, MO June, 2000
64. PECAM-1: Structure and Function Gordon Conference: Cell Contact and Adhesion, Andover, N.H June, 2000
65. Gene Therapy for Lung Cancer and Mesothelioma - Deborah Heart and Lung Center, Browns Mill, N.J June, 2000
66. Review of Clinical Gene Therapy Trials for Lung Cancer and Mesothelioma American Society of Gene Therapy, Boston, MA June, 2000
67. “Gene Therapy for Lung Cancer and Mesothelioma” Aspen Lung Conference, Aspen, Co. June, 2000
68. Augmentation of Immunogene Therapy with TGFbeta blockade American Society of Gene Therapy, Boston, MA June, 2000
69. “Gene Therapy for Malignant Mesothelioma” American Thoracic Society International Meeting, Seattle May, 2000
70. New Approaches to Lung Cancer American Thoracic Society International Meeting, Seattle May, 2000
71. “Gene Therapy for Mesothelioma” New York University School of Medicine May, 2000
72. “Advanced Molecular Biology Techniques” American Thoracic Society International Meeting, San Francisco May, 2000
73. “Gene Delivery Strategies” American Thoracic Society International Meeting, San Francisco May, 2000
74. New Models and Approaches to Mesothelioma American Thoracic Society International Meeting, San Francisco May, 2000
75. Gene Therapy for Cancer American Thoracic Society International Meeting, San Francisco May, 2000
76. “Gene Therapy for Mesothelioma” BioMedicine 98 (AFCR/ASCI/AAP Meetings) May, 2000
77. Lung Cancer Genomics American Thoracic Society International Meeting, San Diego, CA May, 2000
78. Tumor-Stromal Interactions American Thoracic Society International Meeting, San Diego, CA May, 2000
79. Cancer Gene Therapy Program Committee American Society of Gene Therapy Meeting, Seattle, WA May, 2000
80. Cancer Gene Therapy Program Committee American Society of Gene Therapy Meeting-Chairman, Boston, MA May, 2000
81. Gene Therapy for Mesothelioma and Lung Cancer American Thoracic Society International Meeting, San Diego, CA May, 2000
82. Tumor Microenvironment American Thoracic Society International Meeting, San Francisco, CA May, 2000
83. Molecular Basis of Lung Cancer American Thoracic Society International Meeting, Toronto, Canada May, 2000
84. Mouse Models of Lung Cancer American Thoracic Society International Meeting, Toronto, Canada May, 2000
85. Using TGFbeta Blockade Therapy for Cancer. Cancer Center of New Jersey, New Brunswick, N.J. May, 2000
86. “Cell Adhesion Molecules and the Lung” American Thoracic Society International Meeting, San Francisco May, 2000
87. “Gene Therapy and the Lung”- American Thoracic Society International Meeting, Seattle, Washington May, 2000
88. “Advanced Molecular Biology Techniques”- American Thoracic Society International Meeting, San Francisco May, 2000
89. Local organizer International Mesothelioma Interest Group Biannual International Meeting in Philadelphia May, 2000
90. “Gene Therapy and the Lung” American Thoracic Society International Meeting, Seattle May, 2000
91. Immunogene Therapy for Mesothelioma and Metastatic Effusions. University of Toronto (Toronto, Canada) April, 2000
92. “Role of PECAM-1 in Inflammation” Albany Medical College, Albany, NY April, 2000
93. What Tumors Can Teach Us About Atherosclerosis: The Macrophage Connection. Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain April, 2000
94. Ph.D. Thesis Committee for Dr. Arnaud Schepereel University of Lille, France April, 2000
95. Gene Therapy for Thoracic Malignancies Columbia University Medical School, Pulmonary Division, NYC, NY April, 2000
96. (for Respiratory Cell and Molecular Biology Assembly) One of ten Program Chairmen for the International/American Thoracic Society/ American Lung Association International Meeting April, 2000
97. Protein Expression American Thoracic Society International Meeting, San Diego, CA April, 2000
98. Anti-TGF-beta Therapy: Balancing the Pros and Cons AACR Annual Meeting, Washington DC April, 2000
99. Replicating Vectors: Herpes Virus American Thoracic Society International Meeting, Chicago, IL April, 2000
100. Cancer Gene Therapy: Hype or Hope? American Thoracic Society International Meeting, Chicago, IL April, 2000
101. “PECAM-Directed Targeting of Drugs to the Pulmonary Vasculature” American Thoracic Society International Meeting, Toronto, Canada April, 2000
102. Lung Cancer European Respiratory Society Lung Science Conference 2009, Esotoril, Portugal March, 2000
103. Immuno-gene Therapy for Mesothelioma: Successes and Challenges Memorial Sloan Kettering Cancer Center, New York City, NY. March, 2000
104. “Replicating Adenoviral Vectors” Novartis Corp., Gaithersburg, MD March, 2000
105. Immuno-gene Therapy for Pleural Malignancies: Successes and Challenges 2nd N.C.I. Mesothelioma Conference, Washington D.C. March, 2000
106. “Gene Therapy for Malignant Mesothelioma” Mt. Sinai School of Medicine, New York City, New York March, 2000
107. “Gene Therapy for Mesothelioma” Visiting Pulmonary Scholar (sponsored by Duke University, Durham North Carolina) March, 2000
108. “Vascular Immunotargeting of Oxidants and Anti-Oxidants” Visiting Pulmonary Scholar (sponsored by Duke University, Durham North Carolina) March, 2000
109. “PECAM-1: What we know and what we don’t” University of North Carolina, Chapel Hill, NC March, 2000
110. Augmenting Immunotherapy for Mesothelioma Harvard Medical School, Brigham and Women’s Hospital, International Mesothelioma Program. February, 2000
111. Gene Therapy for Mesothelioma Case Western School of Medicine Cancer Center, Cleveland, Ohio February, 2000
112. Immuno-gene Therapy for Pleural Malignancies: Successes and Challenges NYU School of Medicine, Pulmonary Division, NYC, NY January, 2000
113. Approaches to Augment Immunotherapy U.C.L.A. Pulmonary Division, Los Angeles, CA January, 2000
114. Immunotherapy of Mesothelioma International Mesothelioma Interest Group Meeting, Kyoto, Japan January, 2000
115. Clinical trial of an anti-TGFbeta Antibody to Treat Mesothelioma International Mesothelioma Interest Group Meeting, Kyoto, Japan January, 2000
116. Mechanisms and Therapeutic Reversal of Immune Suppression in Cancer Tampa, FL (Moffit Cancer Center and AACR) January, 2000
117. Inhibition of TGFbeta to Augment Immunotherapy. Tampa, FL (Moffit Cancer Center and AACR) January, 2000
118. PECAM-1- A New Player in the Leukocyte-Endothelial Cell Adhesion Cascade The Cleveland Clinic, Cleveland, Ohio. January, 2000
119. Organizing Committee International Mesothelioma Group Meeting, Kyoto, Japan January, 2000
120. Immunotherapy for Mesothelioma IASLC World Conference on Lung Cancer, San Francisco, CA January, 2000
121. Personalized Medicine for Mesothelioma AACR/IASLC Joint Conference on Molecular Origins of Lung Cancer, San Diego, CA January, 2000
122. Gene Therapy for Thoracic Malignancies University of Pittsburgh, Pittsburgh, PA:Department of Pharmacology March, 1995
123. In Vivo Models of Neutrophil-Endothelial Interactions American Academy of Allergy and Immunology International Meeting, NYC, NY February, 1995
124. “PECAM-1: Regulation of Ligand Binding” American Heart Association International Meeting, Dallas, TX November, 1994
125. , “Gene Therapy for Malignant Mesothelioma” University of Michigan, Ann Arbor, MI July, 1994
126. “Role of PECAM-1 In Inflammation” University of Michigan, Ann Arbor, MI July, 1994
127. : “Gene Therapy in the Treatment of Malignant Mesothelioma” American Thoracic Society/American Lung Association Annual International Conference, Boston, Mass. May, 1994
128. Gene Therapy and the Lung American Thoracic Society/American Lung Association Annual International Conference, Boston, Mass. May, 1994
129. “Gene Therapy of the Lung.” College of Physicians and Surgeons of Columbia University, New York, N.Y May, 1994
130. “In vivo Models to Study Cell Adhesion Molecule Function” American Thoracic Society/American Lung Association Annual International Conference, Boston, Mass. May, 1994
131. “Role of Cell Adhesion Molecules in Lung Injury and Repair” American Thoracic Society/American Lung Association Annual International Conference, Boston, Mass. May, 1994
132. “The Role of Integrins in the Lung.” UMDNJ, Robert Wood Johnson Medical School, New Brunswick, N.J April, 1994
133. “Gene Therapy for Thoracic Malignancies.” University of Pittsburgh Cancer Center, Pittsburgh, PA March, 1994
134. “Cytokines and the Regulation of Cell Adhesion Molecules in vivo”. Keystone Conference on Atherosclerosis, Inflammation, and Growth Factor January, 1994
135. Leukocyte Endothelial Interactions: “New Molecules, New Models” Eastern Section, American Federation for Clinical Research, NYC, NY October, 1993
136. “R0ole of Cell Adhesion Molecules in Wound Healing and Tumor Progression” American Thoracic Society International Meeting, San Francisco May, 1993
137. “Cell Adhesion Molecules and the Lung” American Thoracic Society International Meeting, San Francisco May, 1993
138. “The Use of Human/SCID Mouse Chimeras to study Endothelial Cell Adhesion Molecule Regulation During Wound Healing” Invited Speaker- Mini symposium on Angiogenesis and Wound Healing, Experimental Biology 93 (FASEB Meetings), New Orleans, LA March, 1993
139. “Alterations in Epithelial Integrins During Wound Healing” Experimental Biology 93 (FASEB Meetings), New Orleans, LA , Invited Speaker- Symposium on Stromal-Epithelial Interaction in Non-Neoplastic Disease and Development March, 1993
140. “Cell Adhesion Molecules and the Lung- An Overview” Transatlantic Airway Conference: Integrins and Other Adhesion Molecules , Coconut Grove, FL January, 1993
141. “Adhesion Molecules in Inflammation and Asthma” Johns Hopkins Asthma and Allergy Center, Baltimore, MD November, 1992
142. “Role of Cell Adhesion Receptors in Lung Disease” University of Iowa, Pulmonary Division, Iowa City, Iowa October, 1992
143. “Cytokines and Endothelium” American College of Chest Physicians, Chicago, IL October, 1992
144. “Role of Adhesion Molecules in Wound Healing and Cancer” National Institutes of Health, Heart, Lung, Blood Institute Workshop, “Adhesion Molecules in the Lung”, Bethesda, Maryland- Co-Chairman September, 1992
145. Endothelial Cell Adhesion Receptors: New Molecules (PECAM-1), New Models (Human/SCID mouse chimeras) Harvard University, Department of Pathology- Vascular Biology Seminar Series, Boston, MA September, 1992
146. Overview of Cell Adhesion 2nd International Conference on "New Drugs in Allergy and Asthma.", Davos, Switzerland July, 1992
147. Human/SCID Mouse Chimeras: A New Model to Study Endothelial Cell Biology in Inflammation, Wound Healing, and Angiogenesis University of Washington Department of Pathology-Vascular Biology Group, Seattle, Washington June, 1992
148. The Leukocyte-Endothelial Adhesion Cascade Biochemical Pharmacology Discussion Group of the New York Academy of Sciences, New York City, New York March, 1992
149. Cell Adhesion Molecules: An Overview American Academy of Allergy and Immunology 48th Annual Meeting, Orlando, Florida March, 1992
150. PECAM-1: A Novel Vascular Cell Adhesion Molecule Gordon Conference on Cell Adhesion, Andover NH July, 1991
151. Integrins and other Cell Adhesion Molecules of the Lung VANSEAPORT Conference (Pulmonary Divisions of Univ. Vancouver, Univ. of Washington, and Univ. of Oregon Health Sciences), Bend Oregon- Keynote Speaker March, 1991
152. The Cellular Basis of Permeability VANSEAPORT Conference (Pulmonary Divisions of Univ. Vancouver, Univ. of Washington, and Univ. of Oregon Health Sciences), Bend Oregon- Keynote Speaker March, 1991
153. Cell Adhesion Molecules in the Lung Washington University, Pulmonary Section, St. Louis, Mo January, 1991
154. Designer Genes- An Approach to Study Structure/Function Relationships of Cell Adhesion Molecules Southeastern Blood Center of Wisconsin October, 1990
155. Cell Adhesion Receptors and the Lung Yale University, Pulmonary Section, New Haven, CT: Visiting Professor June, 1990
156. Endothelial Cell-Cell and Cell-Substratum Adhesion Receptors Gordon Conference on Permeability, Plymouth, NH June, 1990
157. Spectrum of Aspergillus Lung Disease Yale University, Pulmonary Section, New Haven, CT: Visiting Professor June, 1990
158. Endothelial Adhesion Molecules Tufts/New England Medical School, Boston, MA May, 1990
159. Endothelial Adhesion Molecules ATS Annual Meeting , Boston, MA: Symposium on Cell Adhesion May, 1990
160. Integrins and EndoCAM as Mediators of Endothelial Cell Adhesion American Society of Hematology, Atlanta, GA December, 1989
161. Determinants of Endothelial Permeability ATS Annual Meeting , Cincinnati, OH May, 1989
162. Role of Cell Adhesion Receptors in Lung Diseases Cardiovascular Research Institute, UCSF, San Francisco, CA February, 1989



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Accelerated determination of a LEAD Advances and Progress in Drug Design February, 2012
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-beta: Implications for Anti-Tumor Immunity. | Ballroom 2-3 TGF-beta in Immune Responses: From Bench to Bedside (A2) January, 2011

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.